Bausch + Lomb Gains CE Mark for SeeLyra Femtosecond Laser
VAUGHAN, Ontario — September 11, 2026 Bausch + Lomb Corporation announced that its next-generation SeeLyra™ femtosecond laser has received...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
VAUGHAN, Ontario — September 11, 2026 Bausch + Lomb Corporation announced that its next-generation SeeLyra™ femtosecond laser has received...
SOLANA BEACH, Calif., August 10, 2026 Artelo Biosciences, Inc. announced that the first patient has been dosed in the...
Tokyo, Japan – November 12, 2025 — Waseda University researchers disclosed results from the world’s first time-course observation of...
